Sermorelin Calculator

What Is Sermorelin?

Sermorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH). It corresponds to the first 29 amino acids of natural GHRH(1-44) and is therefore also referred to as GHRH(1-29) or GRF(1-29). This truncated fragment is notable because the first 29 amino acids already contain the complete biologically active core of the molecule. As a result, Sermorelin exerts essentially the same agonist activity at the GHRH receptor as the full-length natural hormone, while being a shorter and simpler sequence to manufacture. In the pharmaceutical literature, Sermorelin is known by the research designation GRF 1-29 and by the historical trade names Geref and sermorelin acetate.

Sermorelin is considered the classic, in a sense original GHRH peptide and was used in research long before the newer, more heavily stabilized variants. It has been studied in the diagnostic assessment of pituitary function and in research into the age-related decline of growth hormone production. Compared to the more modern GHRH analogs CJC-1295 (no DAC) and Tesamorelin, Sermorelin is chemically unmodified. It carries no protective group against enzymatic degradation, which is why its biological half-life is very short.

An important point for understanding: Sermorelin is not a growth hormone, nor is it a ghrelin-type secretagogue. It does not supply GH from an external source — it prompts the pituitary gland to release more of the body's own growth hormone. Because the stimulus only amplifies the natural releasing signal, the regulating mechanisms of the hypothalamic-pituitary axis, in particular the inhibitory action of somatostatin, remain intact. This mechanism fundamentally distinguishes Sermorelin from direct substitution with recombinant growth hormone and shapes its tolerability profile.

Mechanisms of Action

Sermorelin acts exclusively through the GHRH receptor axis and the downstream GH-IGF-1 cascade. Its key mechanisms can be summarized as follows:

• GHRH receptor agonism: Sermorelin binds selectively to the GHRH receptor on the somatotroph cells of the pituitary gland. This binding activates the cAMP signaling pathway inside the cell and triggers the synthesis and release of growth hormone. Because the active GHRH(1-29) fragment contains the full receptor-binding core, its affinity is comparable to that of the natural hormone.
• Preservation of pulsatile GH release: Sermorelin amplifies the natural releasing signal rather than overwriting the endogenous rhythm. The characteristic pulsatile release of growth hormone, in particular the pronounced nocturnal pulses, is preserved. What is enhanced is primarily the amplitude of those pulses, not their timing.
• Rise in IGF-1: The additional growth hormone released stimulates the liver to produce insulin-like growth factor 1 (IGF-1). IGF-1 mediates much of the anabolic and tissue-directed activity of the GH axis and serves in research as a central biomarker for assessing the efficacy of a protocol.
• Preservation of the feedback loop: Because the hypothalamus can continue to release somatostatin, which restrains GH release, the negative feedback of the axis remains intact. This physiological brake limits the risk of excessive GH levels and distinguishes Sermorelin from a constant exogenous GH supply.
• Dependence on a functioning pituitary: Sermorelin can only release GH if the pituitary has the corresponding reserves. Where pituitary function is severely impaired, the response is correspondingly small. For exactly this reason, Sermorelin was historically used as a diagnostic stimulation test to assess GH reserve.
• Very short duration of action: Sermorelin is not chemically protected against degradation by dipeptidyl peptidase-4 (DPP-4). It is therefore rapidly cleaved by enzymes, which explains its short half-life of only about 10 to 20 minutes. The signal is sharply defined and tightly time-limited, but it also fades just as quickly.

Dosage Calculation

Sermorelin is typically administered subcutaneously in research, often in the evening before sleep, to support the natural nocturnal GH pulse. A slow titration ramp is not strictly required, but starting at the lower end of the dose range is a reasonable precaution for observing individual tolerability.

Standard Dosing Parameters

• Conservative dose: 50 mcg (0.05 mg) per injection
• Standard dose: 100 mcg (0.10 mg) per injection
• Higher range: 200-300 mcg (0.20-0.30 mg) per injection
• Frequency: once to three times daily, with evening administration preferred
• Typical syringe: 0.3 mL insulin syringe (29-31 gauge, 6-8 mm needle)
• Common vial sizes: 2 mg and 5 mg lyophilized powder

Example Calculation: 2 mg Vial with 2 mL BAC Water

The most common vial size for Sermorelin is 2 mg. Adding 2 mL of bacteriostatic water gives a concentration of 1 mg/mL (1,000 mcg/mL). This concentration makes small volumes much easier to read on an insulin syringe.

• 50 mcg dose: 50 ÷ 1000 = 0.05 mL (5 units on a U100 syringe)
• 100 mcg dose: 100 ÷ 1000 = 0.10 mL (10 units)
• 200 mcg dose: 200 ÷ 1000 = 0.20 mL (20 units)
• 300 mcg dose: 300 ÷ 1000 = 0.30 mL (30 units)

At 100 mcg once daily, a 2 mg vial provides 20 days of dosing. A 5 mg vial with 2 mL of BAC water yields 2.5 mg/mL, so a 100 mcg dose then corresponds to just 0.04 mL (4 units). Use the Sermorelin calculator above to compute exact volumes for any vial size, reconstitution volume, and target dose.

Injection Site Selection

Sermorelin is administered subcutaneously into the fatty tissue beneath the skin, most commonly into the abdomen in the area around the navel. The outer thigh is also a suitable site. Injection sites should be rotated from day to day to avoid local irritation and hardening of the tissue. The very short half-life of about 10 to 20 minutes means the peptide acts quickly and is cleared just as fast. Consistent, time-aligned administration is therefore more important for a stable research protocol than with longer-acting GHRH analogs.

Reconstitution

Sermorelin is supplied as a lyophilized (freeze-dried) powder in sealed vials and must be reconstituted with bacteriostatic water (BAC water) before use. BAC water contains 0.9% benzyl alcohol, which inhibits microbial growth and extends the usable window of the reconstituted solution. Sterile water for injection is not suitable for multi-dose vials because it offers no preservation.

Step-by-Step Reconstitution Protocol

1. Gather supplies: Sermorelin vial, bacteriostatic water vial, alcohol swabs, a sterile draw needle (18-21 gauge), and your insulin syringe for injection.
2. Wipe the rubber septa of both vials with fresh alcohol swabs and allow them to air-dry for about 30 seconds. Do not touch or blow on the septa after cleaning.
3. Draw the desired volume of BAC water (2 mL is standard for a 2 mg vial) into the draw syringe.
4. Insert the needle into the peptide vial at an angle, directing the tip toward the inner glass wall rather than the powder cake. A direct jet onto the lyophilizate can shear peptide bonds and damage the delicate molecule.
5. Slowly push the plunger, allowing the BAC water to run down the inside wall of the vial and gently wet the powder from the side.
6. Gently swirl or roll the vial between your palms until the powder is completely dissolved. The solution should appear clear and colorless. Do not shake or vortex the vial, as shear forces can denature the peptide.
7. Label the vial with the reconstitution date and concentration (e.g., "Sermorelin 1 mg/mL, reconstituted [date]").

If the solution appears cloudy, discolored, or contains visible particulate matter, discard the vial and do not inject it.

Storage and Shelf Life

• Lyophilized powder (unreconstituted): Store at −20°C for long-term storage, where the powder remains stable for many months. Short-term storage at 2-8°C in the refrigerator is acceptable. Keep away from light and moisture and do not leave at room temperature for extended periods.
• Reconstituted solution: Store in the refrigerator at 2-8°C. Sermorelin is more fragile once dissolved than more robust peptides, so the solution should be used promptly, typically within about 2 to 3 weeks. Keep the vial upright and away from light, and write the reconstitution date prominently on the label.
• Do not freeze reconstituted peptide. Freeze-thaw cycles cause protein aggregation and loss of activity. Once reconstituted, the vial must remain refrigerated throughout its use window.
• Transport: Use an insulated cooler with an ice pack for any travel lasting more than 1-2 hours. Commercial insulated medication pouches maintain 2-8°C for 24-48 hours. Avoid exposure to temperatures above 25°C during transport.

Side Effects and Safety Profile

Sermorelin is among the longest-known GHRH peptides and has been used in humans in diagnostic and age-related research, among other settings. Because its effects are mediated through enhanced growth hormone and IGF-1 activity, the effects to watch for are closely tied to the known actions of the GH axis. All use remains in the research domain.

Commonly Reported Observations

• Injection site reactions such as redness, itching, mild swelling, or brief discomfort. These are among the most frequently documented observations and can be reduced by consistently rotating injection sites.
• Transient facial flushing or a sensation of warmth shortly after injection, which usually subsides within a few minutes.
• Mild headache or a feeling of heaviness or lightheadedness, particularly at the start of a protocol. These observations are usually mild and temporary.
• An altered taste in the mouth or mild nausea immediately after injection, more common when the dose is administered rapidly.

Less Common or Theoretical Concerns

• Effect on glucose metabolism: Growth hormone can reduce insulin sensitivity and affect fasting blood glucose. Because of Sermorelin's very short duration of action, this effect is considered limited, but it should be taken into account in individuals with impaired glucose tolerance.
• Fluid retention and joint discomfort: Enhanced GH activity can theoretically cause mild water retention as well as joint or muscle stiffness. With Sermorelin, such observations are less frequent than with more heavily stabilized GHRH analogs because its peaks are low and short-lived.
• Persistently elevated IGF-1 levels: A sustained increase in IGF-1 is theoretically relevant, since IGF-1 promotes cell growth. Concurrent monitoring of IGF-1 values is common in longer research protocols.

Contraindications

• Active cancer or history of malignancy, as increased GH-IGF-1 activity is theoretically unfavorable
• Pituitary disorders, recent pituitary surgery, or radiation to the head region
• Pregnancy and breastfeeding (insufficient safety data)
• Known hypersensitivity to Sermorelin or any other component of the preparation

At standard research doses, Sermorelin has been described in the published literature as largely well tolerated. Nonetheless, given its action on the endocrine GH axis, caution is warranted, and consultation with a qualified physician is strongly recommended.

Combinations and Stacks

Sermorelin Within the GHRH Class

Sermorelin belongs to the family of GHRH analogs and is closely related functionally to CJC-1295 (no DAC) and Tesamorelin. All three stimulate the same GHRH receptor but differ in stability and duration of action. Sermorelin corresponds to the unmodified GHRH(1-29) fragment with a very short half-life, CJC-1295 without DAC is a modified fragment with improved stability, and Tesamorelin is a fully stabilized GHRH(1-44) analog with the most extensive body of clinical data.

Sermorelin Plus a GHRP — The Dual-Axis Approach

A widely used research concept combines a GHRH analog with a GHRP (growth hormone releasing peptide) such as Ipamorelin. The two peptide classes act through distinct, complementary receptors:

• Sermorelin amplifies the releasing signal at the GHRH receptor and increases the amplitude of GH pulses.
• Ipamorelin acts at the ghrelin receptor and additionally dampens the inhibitory effect of somatostatin, allowing a larger share of the available GH reserve to be released.
• The combined stimulus on both axes produces a more pronounced GH response in models than either peptide achieves alone, without abolishing the pulsatile release pattern.

Other GHRPs discussed alongside Sermorelin in comparable research contexts include Hexarelin, GHRP-6, and GHRP-2. Because the GH-IGF-1 axis is stressed more heavily by a combined stimulus, conservative doses, careful monitoring of glucose and IGF-1, and planned breaks are sensible in research protocols.

Sermorelin as a Standalone

Sermorelin is also used as a standalone compound in research, particularly when the goal is to study a stimulus that is as physiological as possible and closely modeled on natural GHRH. Its very short duration of action makes Sermorelin a well-controlled single peptide whose effects can be tracked through the IGF-1 biomarker. A simple monotherapy protocol is often the first step before more complex combinations are evaluated.

Frequently Asked Questions

How does Sermorelin differ from growth hormone (HGH)?

Sermorelin is not a growth hormone but a GHRH analog. It prompts the pituitary to release more of the body's own growth hormone, whereas HGH supplies the hormone directly from an external source. The key difference lies in feedback: with Sermorelin, the inhibitory action of somatostatin is preserved, so GH levels cannot rise without limit. In addition, the natural, pulsatile release pattern is maintained, which is not the case with a constant supply of HGH.

What is the difference between Sermorelin and CJC-1295?

Both are GHRH analogs and stimulate the same receptor. Sermorelin corresponds to the unmodified GHRH(1-29) fragment and is broken down very quickly. CJC-1295 without DAC is a modified fragment with targeted amino acid substitutions that make it more resistant to enzymatic degradation, which is why its duration of action is longer. Sermorelin is therefore the closest to natural GHRH, while CJC-1295 was optimized for extended stability.

Why is Sermorelin used in the evening?

The body's largest natural GH release occurs during the first hours of deep sleep. An evening injection of Sermorelin is intended to amplify this physiological pulse rather than create an additional, off-schedule GH surge. The very short half-life of about 10 to 20 minutes suits this concept well, as the signal stays tightly time-limited and coincides with the nocturnal pulse.

Why does Sermorelin have such a short half-life?

Sermorelin is chemically unmodified and structurally closely matches the natural GHRH fragment. It carries no protective group against dipeptidyl peptidase-4 (DPP-4), an enzyme that rapidly cleaves GHRH-type peptides. As a result, Sermorelin is broken down very quickly, with a half-life of only about 10 to 20 minutes. This short duration of action is intentional, as it produces a sharply defined, physiologically natural signal.

Should Sermorelin be used in a fasted state?

Because growth hormone and insulin partly act against each other, a high insulin level following a carbohydrate-rich meal dampens the GH response. Research protocols therefore often recommend timing the injection with a gap after the last substantial meal. With evening administration before sleep, this gap often arises naturally.

Is post-cycle therapy (PCT) required?

Sermorelin does not act on the hypothalamic-pituitary-gonadal axis and does not suppress the body's own testosterone production. A classic PCT, of the kind common after androgenic substances, is therefore not required. Because Sermorelin only amplifies the natural GHRH signal, the pituitary generally recovers after discontinuation without any further measures.

Is Sermorelin prohibited in sports drug testing?

Yes. Sermorelin falls under the WADA prohibited list as a growth hormone-releasing factor and GH secretagogue and is banned in sport both in and out of competition. Athletes subject to WADA-compliant testing should treat Sermorelin as a prohibited substance and verify the anti-doping rules applicable to their sport before any use.

Can Sermorelin be mixed with a GHRP in the same syringe?

Some research protocols combine a GHRH analog and a GHRP in a single syringe immediately before injection. In general, however, it is safer to reconstitute each peptide individually and inject them separately, since their combined stability in solution is not well characterized. Separate injections at adjacent sites add minimal inconvenience while eliminating the risk of dosing errors.

Medical Disclaimer: The information on this page is provided for educational and research purposes only. Sermorelin is not an approved drug or medical treatment within the scope of this offering and is provided strictly for research use. Nothing on this page constitutes medical advice, diagnosis, or a recommendation to use any specific compound. Always consult a qualified healthcare professional before beginning any peptide protocol. BergdorfBio assumes no liability for the use or misuse of the information presented here.